title: [Interstitial pneumonia connected with rituximab therapy--case report].
abstract: Rituximab (RTX) is a monoclonal antibody against the CD20 antigen found on the surface of B cells. RTX causes cell lysis and is therefore used to treat lymphomas, leukaemias, transplant rejection and certain autoimmune disorders. Pulmonary adverse events associated with RTX have been reported in literature. We describe a patient with follicular lymphoma treated with R-CHOP scheme (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) who had pulmonary symptoms during chemotherapy which were diagnosed as rituximab-induced interstitial pneumonia. Symptoms and radiological changes resolved with prednisone therapy.
authors.affiliation: I Klinika Chorób Płuc Instytutu Gruźlicy i Chorób Płuc, ul. Płocka 26, Warsaw. d.wyrostkiewicz@igichp.edu.pl
authors.forename: Dorota
authors.initials: D
authors.lastname: Wyrostkiewicz
authors.forename: Wojciech
authors.initials: W
authors.lastname: Skorupa
authors.forename: Inga
authors.initials: I
authors.lastname: Barańska
authors.forename: Jan
authors.initials: J
authors.lastname: Kuś
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D005260:Female; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000000981:diagnostic imaging*; D008224:Lymphoma, Follicular / Q000188:drug therapy*; D008875:Middle Aged; D011859:Radiography; D012307:Risk Factors; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab